ArticleThe international journal of behavioral nutrition and physical activity2026
Vigorous intermittent lifestyle physical activity (VILPA) and mortality risk among US adults: a wearables-based national cohort study.
Article in The international journal of behavioral nutrition and physical activity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVigorous intermittent lifestyle physical activity (VILPA) completed through normal daily living may offer a time-efficient avenue to accrue physical activity in a behaviourally sustainable manner. However, no research to date has explored its association with mortality in a nationally representative population. This study aimed to examine the dose-response association between VILPA and mortality risk in a nationally representative sample of US adults.
methodsThis study included a nationally representative sample of 3293 US adults from the 2011-14 National Health and Nutrition Examination Survey (NHANES) who self-reported no participation in structured exercise (52.3% female; mean age: 50.7 [SD: 16.6 years]. The dose-response relationship between VILPA and all-cause mortality was estimated using multivariable-adjusted cubic splines. Average daily frequency (bouts/day) and duration (minutes/day) of VILPA bouts lasting up to one minute were measured using a wrist-worn accelerometer.
resultsOver the mean (SD) 6.7 (1.4) year follow-up period, 290 all-cause mortality events occurred. Compared to the referent point (0 bouts per day), there was an L-shaped dose-response association where the median frequency (5.3 bouts per day) was associated with a 44% lower risk of all-cause mortality (HR: 0.56; 95% CI: 0.39, 0.82). The dose response curve was less steep beyond approximately 8 bouts per day (HR: 0.46; 95% CI: 0.28, 0.77). Findings for the median frequency of VILPA bouts (5.3 bouts per day) remained consistent after excluding participants with poor health (HR: 0.51: 95% CI: 0.29, 0.87) and those who completed no VILPA (HR: 0.57: 95% CI: 0.38, 0.86). When excluding adults with prevalent cardiovascular disease or cancer at baseline (n = 2,731, 152 events), the dose-response relationship was similar, although the 95% CIs crossed unity for most of the curve (e.g. median frequency of VILPA bouts HR: 0.68: 95% CI: 0.41, 1.11).
conclusionsIn a nationally representative sample of US adults, short bursts of intermittent vigorous physical activity were associated with a lower risk of mortality. Excluding those with prevalent cardiovascular disease and cancer led to attenuated dose-response curves and wider confidence intervals, suggesting that the observed relationships may, at least partly, be driven by existing disease-induced reverse causation. While these results highlight some potential of VILPA as a time-efficient source of activity, additional observational studies with longer follow up and larger sample sizes are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.